This phase II trial is investigating the use of local consolidation radiotherapy in men with non-metastatic, castrate resistant prostate cancer.
This trial is treating patients with castration-resistant prostate cancer (CRPC).
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Trans Tasman Radiation Oncology Group (TROG)
This trial will test the hypothesis that the addition of consolidation radiotherapy to darolutamide will improve the clinical outcome of patients, compared to those patients receiving darolutamide alone. Patients will be randomised to receive 600mg darolutimide alone, twice daily, or in combination with local consolidative radiotherapy.
Recruiting Hospitals Read More